Mechanisms of resistance to antiretroviral drugs - Clinical implications

AIDS Reviews

Volumn 4, Issue 2, 2002, Pages 64-82

  De Mendoza, Carmen ^a   Gallego, Oscar ^a   Soriano, Vincent ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antiretroviral drugs; Drug resistance; HIV; NAMs

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; BINDING AFFINITY; CLINICAL TRIAL; CODON; COMPETITIVE INHIBITION; DEPHOSPHORYLATION; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME SUBSTRATE; GENE INSERTION; GENE MUTATION; GENE STRUCTURE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MULTIDRUG RESISTANCE; NONHUMAN; PREDICTION; REVIEW; VIRAL GENETICS; VIRUS INHIBITION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; MUTATION;

DRUG RESISTANCE, VIRAL; HIV; HIV PROTEASE INHIBITORS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035988450     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (164)

1. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
2. Pol gene quasi-species of HIV: Mutations associated with drug resistance in virus from patients undergoing no drug therapy
3. Introduction of drug resistance testing in clinical practice
4. Replicative fitness of protease inhibitor-resistant mutants of HIV type 1
5. Interference between D30N and L90M in selection and development of protease inhibitor-resistant HIV type 1
6. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure
7. Sequencing of antiretroviral drugs
8. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 RT
9. The enzymatic basis for thymidine analogue resistance in HIV-1
10. Nucleoside reverse transcriptase inhibitor resistance
11. Resistance to nucleoside analogue reverse transcriptase inhibitors mediated by HIV type 1 p6 protein
12. The presence of NAM is highly correlated with reduced susceptibility to all NRTI
13. Extent of cross-resistance between agents used to treat HIV type 1 infection in clinically derived isolates
14. Ordered appearance of zidovudine resistance mutations during treatment of 18 HIV-positive subjects
15. Switch to unusual amino acids at codon 215 of the HIV-1 RT gene in seroconvertors infected with zidovudine-resistant variants
16. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naïve persons
17. Prevalence of codon 215 polymorphisms in antiretroviral-experienced HIV-infected patients which might reflect reversion of drug-resistant genotypes
18. Genotypic and phenotypic analysis of HIV-1 isolates from patients on prolonged stavudine therapy
19. Lack of emergence of genotypic resistance to stavudine after two years of monotherapy
20. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy
21. HIV-1 RT genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years
22. Selection of zidovudine resistance mutations and escape of HIV type 1 from antiretroviral pressure in stavudine-treated pediatric patients
23. Emergence of zidovudine and multidrug resistance mutations in the HIV-1 RT gene in therapy-naïve patients receiving stavudine plus didanosine combination therapy
24. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
25. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine
26. Comparison of genotypic and phenotypic resistance patterns of HIV-1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine
27. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
28. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy
29. Resistance profile of the HIV-1 RT inhibitor abacavir (1592U89) after monotherapy and combination therapy
30. HIV-1 RT genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy
31. Prevalence and clinical significance of zidovudine resistance mutations in HIV isolated from patients after long-term zidovudine treatment. ACTG 116B/117
32. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived HIV-1 isolates
33. Effect of baseline nucleoside-associated resistance on response to tenofovir therapy: Integrated analysis of studies 902 and 907
34. Analysis of clinical isolates and site-directed mutants reveals the genetic determinants of didanosine resistance
35. A rational approach to the selection and sequencing of nucleoside / nucleotide analogues: A new paradigm
36. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase
37. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the RT enzyme
38. Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential
39. Lamivudine resistance of HIV-1 does not delay development of resistance to non-nucleoside HIV-1 specific RT inhibitors as compared with wild type HIV-1
40. Rapid in vitro selection of HIV type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of RT
41. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
42. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège
43. Absence of zidovudine resistance in antiretroviral-naïve patients following zidovudine/lamivudine/protease inhibitor combination therapy: Virologic evaluation of the AVANTI 2 and AVANTI 3 studies
44. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir
45. The role of abacavir in antiretroviral therapy-experienced patients: Results from a randomised, double blind trial: CNA3002 European Study Team
46. Multiple concurrent RT and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
47. Highly drug-resistant HIV-1 isolates are cross-resistant to many of the current anti-HIV compounds in clinical development
48. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 RT
49. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors
50. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy
51. Impact of HIV-1 protease, RT, cleavage site, and p6 mutations on the virologic response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs
52. Proline residues in HIV-1 p6gag exert a cell type-dependent effect on viral replication and virion incorporation of pol proteins
53. Effect of mutations affecting the p6 gag protein HIV virus particle release
54. Mutations of the HIV-1 p6gag domain results in reduced retention of pol proteins during virus assembly
55. Role of the C terminus Gag protein in HIV-1 virion assembly and maturation
56. Autoprocessing of HIV-1 protease is tightly coupled to protein folding
57. Polymorphisms in the p6/p6* of HIV-1 Gag are associated with hypersusceptibility to protease inhibitors
58. High prevalence of insertions in HIV p6 PTAP region in drug naïve individuals starting anti-retroviral therapy: Potential clinical implications
59. Mutations at the HIV-1 p6 region in naïve and pre-treated HIV-infected patients
60. Genetic variation in p6gag in primary HIV infection
61. Combination therapy with zidovudine and didanosine selects for drug-resistant HIV-1 strains with unique patterns of pol gene mutations
62. Emergence of HIV-1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
63. Multiple dideoxynucleoside analogue-resistant HIV-1 strains isolated from patients from different European countries
64. Prevalence and characteristics of multinucleoside-resistant HIV-1 among European patients receiving combinations of nucleoside analogues
65. Multiple drug resistance genotype causing failure of antiretroviral treatment in an HIV-infected patient heavily exposed to nucleoside analogues
66. Genotypic and phenotypic changes during culture of a multinucleoside-resistant HIV-1 strain in the presence and absence of additional RT inhibitors
67. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir
68. Structure of a covalently trapped catalytic complex of HIV-1 RT: Implications for drug resistance
69. A 6-basepair insert in the RT gene of HIV-1 confers resistance to multiple nucleoside inhibitors
70. A family of insertion mutations between codons 67 and 70 of HIV-1 RT confer multinucleoside analog resistance
71. Prevalence and genetic heterogeneity of the RT T69S-S-X insertion in pretreated HIV-infected patients
72. Multidrug resistance genotypes (insertions in the β3-β4 finger subdomain and MDR mutations) of HIV-1 RT from extensively treated patients: Incidence and association with other resistance mutations
73. Insertion of two amino acids combined with changes in RT containing tyrosine 215 of HIV-1 resistant to multiple nucleoside analogs
74. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance
75. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408
76. Potential mechanisms for sustained antiretroviral efficacy of AZT-3TC combination therapy
77. Emergence of dual resistance to zidovudine and lamivudine in HIV-1 infected patients treated with zidovudine plus lamivudine as initial therapy
78. The M184V mutation in the RT of HIV type 1 impairs rescue of chain-terminated DNA synthesis
79. Lamivudine in combination with zidovudine, stavudine or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial (ACTG 306)
80. HIV-1 expressing the lamivudine-associated M184V mutation in RT shows increased susceptibility to adefovir and decreased replication capability in vitro
81. A novel polymorphism at codon 333 of HIV-1 RT can facilitate dual resistance to zidovudine and lamivudine
82. Prevalence of the codon 333 resistance genotype in naïve and pre-treated patients in Spain
83. A novel HIV-1 RT mutational pattern confers phenotypic lamivudine resistance in the absence of mutation M184V
84. Prevalence of novel lamivudine-resistant genotypes (E44D/A, V118I) in naïve and pre-treated HIV-infected individuals
85. Prevalence of the mutational pattern E44D/A and/or V118I in the RT gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors
86. Antiretroviral resistance mutations (revised April 2001)
87. Lamivudine resistance in HIV-1 RT involves steric hindrance with beta-branched amino acids
88. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
89. Nevirapine-resistant HIV: Kinetics of replication and estimated prevalence in untreated patients
90. Emergence of drug resistance mutations in HIV-2-infected subjects undergoing antiretroviral therapy
91. Specific inhibition of the RT of HIV-1 and the chimeric enzymes of HIV type 1 and 2 by non-nucleoside inhibitors
92. Use of chimeric HIV types 1 and 2 RT for structure-function analysis and for mapping susceptibility to non-nucleoside inhibitors
93. Analysis of pol gene heterogeneity, viral quasispecies and drug resistance in individuals infected with group O strains of HIV type 1
94. Susceptibility of HIV-1 group O isolates to antiretroviral agents: In vitro genotypic and phenotypic analyses
95. Reduced susceptibility of HIV-1 from patients with primary HIV infection to non-nucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites
96. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy
97. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naïve patients
98. DMP-266: A novel, highly potent non-nucleoside inhibitor of the HIV-1 RT
99. Non-nucleoside reverse transcriptase inhibitors
100. Delavirdine in combination with zidovudine in treatment of HIV-1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial
101. NNRTI resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
102. Mutations in retroviral genes associated with drug resistance
103. Efavirenz and adefovir based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
104. Can early failure with nevirapine be rescued with efavirenz?
105. HIV-1 mutations selected in patients failing efavirenz combination therapy
106. A proline-to-histidine substitution at position 225 of HIV-1 RT sensitizes HIV-1 RT to BHAP U-90152
107. A novel HIV-1 RT mutation (M230L) confers NNRTI resistance and dose-dependent stimulation of replication
108. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor-binding pocket of HIV type 1 reverse transcriptase
109. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in 3TC-experienced patients: Results of ACTG 370
110. Non-nucleoside reverse transcriptase inhibitors
111. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure
112. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease
113. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials
114. Resistance to protease inhibitors
115. Resistance to HIV-1 protease inhibitors
116. Drug resistance during indinavir therapy is caused by mutations in the protease gene and its Gag substrate cleavage sites
117. Second locus involved in HIV-1 resistance to protease inhibitors
118. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors
119. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
120. Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies
121. In vitro selection and characterization of HIV-1 isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
122. Resistance during early virologic rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347
123. ABT-378, a highly potent inhibitor of HIV protease
124. In vitro selection and characterization of HIV-1 variants with increased resistance to ABT-378. A novel protease inhibitor
125. Efficacy and safety of lopinavir/ritonavir (Kaletra) in heavily pre-treated HIV-infected patients
126. Genetic correlates of in vivo viral resistance to indinavir, a HIV-1 protease inhibitor
127. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing HAART with nelfinavir or indinavir
128. HIV-1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
129. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy
130. Impact of baseline polymorphisms in RT and protease on outcome of HAART in HIV-1-infected African patients
131. High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid
132. Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease, which retains susceptibility to protease inhibitors
133. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
134. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy
135. A preliminary evaluation of nelfinavir mesylate, an inhibitor of HIV-1 protease, to treat HIV infection
136. Resistance mutations in patients experiencing early failure with nelfinavir-containing triple combinations
137. Different pathways to nelfinavir genotypic resistance in HIV-1 subtypes B and G
138. HIV-1 fitness and antiretroviral drug resistance
139. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
140. Phenotypic and genotypic analysis of clinical isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples
141. Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants
142. Drug resistance and predicted virologic responses to HIV-1 protease inhibitor therapy
143. Functional correlates of insertion mutations in the protease gene of HIV-1 isolates from patients
144. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
145. HIV-1 viral background plays a major role in development of resistance to protease inhibitors
146. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during sub-optimal therapy
147. Retracing the evolutionary pathways of HIV-1 resistance to proteinase inhibitors. Virus fitness in the absence and in the presence of drug
148. Mutation patterns of the RT and protease genes in HIV-1-infected patients undergoing combination therapy: Survey of 787 sequences
149. HIV reverse transcriptase and protease sequence database: An expanded model integrating natural language text and sequence analysis
150. In vitro resistance profile of the HIV-1 protease inhibitor BMS-232632
151. Prevalence of the HIV protease inhibitor mutation N88S causing hypersensitivity to amprenavir
152. A mutation in HIV-1 protease, N88S, that causes in vitro hypersensitivity to amprenavir
153. HIV-1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo
154. Hypersusceptibility to protease inhibitors associated with mutated proteases at codons 30 and 88 in treated patients
155. Identification of genotypic changes in HIV protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
156. Quantitation of lopinavir resistance and cross-resistance and phenotypic contribution of mutations shared with other protease inhibitors
157. Analysis of mutational patterns associated with response to lopinavir/ritonavir in multiple protease inhibitor-experienced patients
158. Lopinavir resistance of amprenavir-selected, replication-impaired mutants of HIV
159. Differential impact of specific key mutations in HIV protease on phenotypic susceptibility to amprenavir and lopinavir
160. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir
161. Comparison of the efficacy, safety, and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors
162. Natural variation in HIV-1 protease, Gag p7 and p6, and cleavage sites within Gag/Pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by HIV-1
163. Competitive inhibition of HIV-1 protease by the gag-pol transframe protein
164. Deletion of sequences upstream of the proteinase improves the proteolytic processing of HIV-1